Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now early-phase tilt small index

Tolerance: early-phase trial registry

2 of 8 indexed Tolerance trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #2,176 of 28,707 conditions by registered trial count.

Jump to open trials → Trial finder

8 US clinical trials · 2 currently recruiting · #2,176 of 28,707 conditions by registered trial count

Tolerance: 8 US clinical trials tracked, 2 recruiting.

Tolerance is the subject of 8 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Mondelēz International, running 1 of these trials.

Enrollment posture brief

Registry condition tolerance

OPEN 2 | RECR 25% | LATE 0 | EARLY 2 | RANK #2176 | SPON 1

Volume-matched condition peers

Nearest open-share peer: Abdominal Pain (25% recruiting · 20 trials)

Activity, Motor75%Achalasia50%Abdominal Cancer25%Acne Scars - Mixed Atrophic 25%Tolerance (this)25%
Open-enrollment share among volume-matched conditions near Tolerance

Tolerance lists 2 open slots (25% of 8 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Tolerance on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Tolerance is recruiting below its size-band peers.

    2 of 8 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Tolerance trials is spread across many organizations.

    Mondelēz International accounts for 1 of 8 trials (12.5%). 8 distinct sponsors appear on at least one study for this condition label.

  3. Most Tolerance trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 8 trials that report a genuine target (sentinel values excluded). 7 of those (87.5%) plan for fewer than 100 participants.

  4. Tolerance research is mostly interventional.

    7 interventional and 1 observational studies make up this index (87.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12

Phase Distribution

PhaseTrial count
Phase 1 2

Top Sponsors

Mondelēz International 1 trials
University of Memphis 1 trials
Jeffrey Veale, MD 1 trials
Buck Institute for Research on Aging 1 trials
University of Vermont 1 trials
University of Illinois at Urbana-Champaign 1 trials
University of Michigan 1 trials
University of Chicago 1 trials

Named interventions

Most-linked intervention names on Tolerance records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Non-ketone placebo Other
1 trials
Acute intake of one of the products (active comparator 1 to 9) or Placebo comparator Other
1 trials
Liquid IV with amino acids (three servings) Dietary supplement
1 trials
Liquid IV with amino acids (two servings) Dietary supplement
1 trials
Liquid IV with amino acids (one serving) Dietary supplement
1 trials
Crystal Light (once serving) Dietary supplement
1 trials
Agave Inulin Other
1 trials
T-Break Guide Behavioral
1 trials

US sites by state

Facility locations filed on Tolerance trials. A trial with sites in several states counts in each.

Illinois 3 trials
California 2 trials
Vermont 1 trials
Tennessee 1 trials
Michigan 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Tolerance page

8 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Tolerance condition card totals 8 registered trials; most-linked intervention Non-ketone placebo; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.